Holmium laser enucleation of the prostate: surgical, functional, and quality-of-life outcomes upon extended follow-up
Int. braz. j. urol; 42 (2), 2016
Publication year: 2016
ABSTRACT Objectives:
To evaluate the long-term surgical, functional, and quality-of-life (QoL) outcomes after Holmium laser enucleation of the prostate (HoLEP) in patients with symptomatic benign prostatic hyperplasia (BPH).Materials and Methods:
We retrospectively reviewed recorded data on patients who underwent HoLEP between June 2002 and February 2005. Ninety-six patients were enrolled. Demographic, perioperative, and postoperative data were recorded. On follow-up, International Prostate Symptom Scores (IPSSs), prostate-specific antigen (PSA) levels, QoL scores, peak uroflowmetric data (Qmax values), and post-voiding residual urine volumes (PVR volumes), were recorded. Complications were scored using the Clavien system. Statistical significance was set at p<0.05.Results:
The mean follow-up time was 41.8±34.6 months and the mean patient age 73.2±8.7 years. The mean prostate volume was 74.6±34.3mL. Significant improvements in Qmax values, QoL, and IPSSs and decreases in PSA levels and PVR volumes were noted during follow-up (all p values=0.001). The most common complication was a requirement for re-catheterisation because of urinary retention. Two patients had concomitant bladder tumours that did not invade the muscles. Eight patients (8.3%) required re-operations; three had residual adenoma, three urethral strictures, and two residual prostate tissue in the bladder. Stress incontinence occurred in one patient (1%). All complications were of Clavien Grade 3a. We noted no Clavien 3b, 4, or 5 complications during follow-up.Conclusions:
HoLEP improved IPSSs, Qmax values, PVR volumes, and QoL and was associated with a low complication rate, during extended follow-up. Thus, HoLEP can be a viable option to transurethral resection of the prostate.
Estudios de Seguimiento, Terapia por Láser/efectos adversos, Terapia por Láser/métodos, Láseres de Estado Sólido/uso terapéutico, Tempo Operativo, Complicaciones Posoperatorias, Próstata/patología, Próstata/cirugía, Antígeno Prostático Específico/sangre, Hiperplasia Prostática/patología, Hiperplasia Prostática/cirugía, Calidad de Vida, Reproducibilidad de los Resultados, Estudios Retrospectivos, Factores de Tiempo, Resultado del Tratamiento, Vejiga Urinaria/cirugía